Analysts Remain Bullish on Delcath (DCTH) as Company Seeks Priority Review of CHEMOSAT

Analysts at Cowen and Company reiterated an Outperform rating on shares of Delcath (Nasdaq: DCTH). Analysts said they believe CHEMOSAT meets the FDA’s criteria for a priority designation and also believe that the priority review will significantly accelerate the regulatory process.

“Based on the update that Delcath management provided and the progress that the company has been able to demonstrate in commercializing CHEMOSAT in the EEA, we remain optimistic on the regulatory decision in the U.S. and remain bullish on the Delcath Story,” said analyst Edward Nash.

If Delcath is successful in their attempt for receive a priority review of the CHEMOSTAT, the PDUFA date will be Feb 2013. Otherwise a June review is likely under a standard review, noted the report.

For an analyst ratings summary and ratings history on Delcath Systems click here. For more ratings news on Delcath Systems click here.

Shares of Delcath Systems closed at $1.68 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market
• New Street Research Upgrades Micron Technology (MU) to Buy
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy